Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
What's Your Reaction?
like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0
